	US 12,139,538 B2
	Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
Renier J. Brentjens, Short Hills, NJ (US); Eric L. Smith, Brookline, MA (US); and Cheng Liu, Emeryville, CA (US)
Assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US); and EUREKA THERAPEUTICS INC., Emeryville, CA (US)
Filed by MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US); and EUREKA THERAPEUTICS, INC., Emeryville, CA (US)
Filed on May 27, 2021, as Appl. No. 17/332,853.
Application 17/332,853 is a division of application No. 15/614,108, filed on Jun. 5, 2017, granted, now 11,059,891.
Application 15/614,108 is a continuation of application No. PCT/US2015/064134, filed on Dec. 4, 2015.
Claims priority of provisional application 62/088,164, filed on Dec. 5, 2014.
Prior Publication US 2023/0020729 A1, Jan. 19, 2023
Int. Cl. C07K 16/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 9/12 (2006.01); C12N 15/86 (2006.01)

CPC C07K 16/283 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/001129 (2018.08); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/7056 (2013.01); C07K 14/70578 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); C12N 9/1205 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01); C12N 2740/10043 (2013.01); C12N 2740/13043 (2013.01); C12N 2840/203 (2013.01)]

31 Claims

1. A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular domain, wherein the extracellular antigen-binding domain specifically binds to Fc Receptor-Like 5 (FcRL5) and comprises:

(a) a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:3, and a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:4;

(b) a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:115, and a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:116;

(c) a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:219, and a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:220; or

(d) a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:235, and a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO: 236.